New ALK inhibitor more than doubled progression-free time versus crizotinib in NSCLC
In a Chinese phase 3 trial of 275 patients with ALK-positive advanced lung cancer, dirozalkib delayed progression to a median of 29.5 months against 12.9 on crizotinib. No survival result yet.
| Group | Value (months) |
|---|---|
| Dirozalkib | 29.5 |
| Crizotinib | 12.9 |
A selective ALK inhibitor, dirozalkib, more than doubled the time patients lived without their lung cancer worsening compared with crizotinib, the older standard, in a phase 3 randomised trial run in China and published in Cancer Communications [s1]. The effect on progression was large and was confirmed by an independent review. But progression-free survival is not the same as living longer, overall survival was not the headline result, and the comparator was a first-generation drug — so what the trial shows needs to be placed carefully.
The drug and the target
Around one in 20 non-small-cell lung cancers (NSCLC) are driven by a rearranged ALK gene, and these cancers can be treated with drugs that block the ALK enzyme. Crizotinib was the first such drug approved, which is why it has long served as a benchmark [s1]. Dirozalkib — carried in the trial registry under the development code XZP-3621 — is described by the investigators as a highly selective ALK inhibitor with activity inside the brain and against some crizotinib-resistant mutations [s1][s2].
What the trial did
DIAMOND-2 was a multicentre, randomised, open-label phase 3 trial [s1]. It enrolled adults with ALK-inhibitor-naïve, ALK-positive advanced NSCLC who had either received no prior systemic therapy or had progressed on, or could not tolerate, one earlier chemotherapy regimen [s1]. Patients were randomly assigned 1:1 to dirozalkib at 500 mg once daily or crizotinib at 250 mg twice daily, and the primary endpoint was progression-free survival as judged by the treating investigators [s1]. The trial is registered as NCT05204628 [s2].
Between 24 January 2022 and 30 April 2023, 275 patients were randomised — 137 to dirozalkib and 138 to crizotinib [s1]. By the data cutoff of 31 May 2025, median follow-up was 32.8 months in the dirozalkib group and 31.6 months in the crizotinib group [s1].
What it found
Median investigator-assessed progression-free survival was 29.5 months with dirozalkib (95% CI 20.3 to not reached) against 12.9 months with crizotinib (95% CI 11.1 to 17.6), a hazard ratio of 0.47 (95% CI 0.34 to 0.66; P less than 0.001) [s1]. When the scans were re-read by a blinded independent central review — a check on whether knowing the assignment had swayed the investigators — the advantage held: median progression-free survival of 27.5 versus 12.9 months, hazard ratio 0.54 (95% CI 0.39 to 0.74; P less than 0.001) [s1].
On safety, severe (grade 3 or worse) treatment-emergent adverse events were less frequent with dirozalkib than with crizotinib (60.6% versus 72.5%), and such events led to treatment being stopped in 2.2% of the dirozalkib group against 7.2% of the crizotinib group [s1].
How to read it
The size of the progression benefit — a hazard ratio near 0.5 on both investigator and blinded review — is the kind of result that supports a drug's use, and the independent re-read matters because this was an open-label trial, in which patients and doctors knew which drug was given. Blinding the imaging review guards against the bias that open-label designs invite, and here it reproduced the effect [s1].
Three limits keep it in proportion. First, the trial measured progression-free survival, not overall survival; whether patients ultimately live longer is a separate question the abstract does not answer. Second, it was conducted entirely in China, so how far the result generalises is untested [s1]. Third, and most important for practice, the comparator was crizotinib, a first-generation ALK inhibitor. In many health systems later-generation ALK drugs have already displaced crizotinib as the first choice, and this trial did not test dirozalkib against those agents — so it shows dirozalkib is better than an older benchmark, not that it is better than the current best option.
What to watch
The decisive follow-on questions are overall survival as the data mature, how dirozalkib controls disease that has spread to the brain — a common and serious problem in ALK-positive lung cancer that the registry flags as a design interest but the abstract does not quantify — and, eventually, a comparison against the newer ALK inhibitors that set today's standard [s1][s2]. For now this is a strong progression result against an old comparator in a single-country trial: enough to mark dirozalkib as active, not enough on its own to rank it against its modern rivals.
This article describes clinical-trial results and is not medical advice. Decisions about cancer treatment are for patients and their treating oncologists.
Sources
- Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial — Cancer Communications , November 10, 2026
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib (NCT05204628) — ClinicalTrials.gov
More on
Adjuvant crizotinib did not improve survival in resected ALK-positive lung cancer
The publicly funded E4512 trial found two years of crizotinib after surgery did not prolong disease-free survival against observation, with a hazard ratio of 1.08 and no safety upside.
SKYSCRAPER-01 confirms tiragolumab added nothing in PD-L1-high lung cancer
The final analysis of Roche's phase 3 trial found the anti-TIGIT antibody did not significantly extend progression-free or overall survival when added to atezolizumab in 521 patients.
Adding immunotherapy to radiation did not help early-stage lung cancer survival
In the phase 3 SWOG/NRG S1914 trial, adding atezolizumab to stereotactic radiotherapy for high-risk, inoperable early lung cancer left 2-year survival at 82% in both groups and caused more serious side effects.
A bispecific antibody-drug conjugate beat chemotherapy in treated EGFR lung cancer
In PANKU-Lung01, 432 people with EGFR-mutated NSCLC that progressed on a third-generation EGFR tablet got izalontamab brengitecan or chemotherapy. Median progression-free survival was 11.1 versus 5.7 months.